000118140 001__ 118140
000118140 005__ 20231219145819.0
000118140 0247_ $$2doi$$a10.3390/ani11113121
000118140 0248_ $$2sideral$$a126830
000118140 037__ $$aART-2021-126830
000118140 041__ $$aeng
000118140 100__ $$0(orcid)0000-0001-5084-6555$$aGarcía-Belenguer S.$$uUniversidad de Zaragoza
000118140 245__ $$aGut microbiota in canine idiopathic epilepsy: Effects of disease and treatment
000118140 260__ $$c2021
000118140 5060_ $$aAccess copy available to the general public$$fUnrestricted
000118140 5203_ $$aEpilepsy is one of the most common neurological disorders in humans and dogs. The structure and composition of gut microbiome associated to this disorder has not yet been analyzed in depth but there is evidence that suggests a possible influence of gut bacteria in controlling seizures. The aim of this study was to investigate the changes in gut microbiota associated to canine idiopathic epilepsy (IE) and the possible influence of antiepileptic drugs (AEDs) on the modulation of this microbiota. Faecal microbiota composition was analyzed using sequencing of bacterial 16S rRNA gene in a group of healthy controls (n = 12) and a group of epileptic dogs both before (n = 10) and after a 30-day single treatment with phenobarbital or imepitoin (n = 9). Epileptic dogs showed significantly reduced abundance of GABA (Pseudomonadales, Pseudomonadaceae, Pseudomonas and Pseudomona_graminis) and SCFAs-producing bacteria (Peptococcaceae, Ruminococcaceae and Anaerotruncus) as well as bacteria associated with reduced risk for brain disease (Prevotellaceae) than control dogs. The administration of AEDs during 30 days did not modify the gut microbiota composition. These results are expected to contribute to the understanding of canine idiopathic epilepsy and open up the possibility of studying new therapeutic approaches for this disorder, including probiotic intervention to restore gut microbiota in epileptic individuals. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
000118140 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000118140 592__ $$a0.61$$b2021
000118140 590__ $$a3.231$$b2021
000118140 593__ $$aVeterinary (miscellaneous)$$c2021$$dQ1
000118140 591__ $$aVETERINARY SCIENCES$$b16 / 145 = 0.11$$c2021$$dQ1$$eT1
000118140 593__ $$aAnimal Science and Zoology$$c2021$$dQ1
000118140 591__ $$aAGRICULTURE, DAIRY & ANIMAL SCIENCE$$b13 / 62 = 0.21$$c2021$$dQ1$$eT1
000118140 594__ $$a2.7$$b2021
000118140 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000118140 700__ $$0(orcid)0000-0002-5306-9365$$aGrasa L.$$uUniversidad de Zaragoza
000118140 700__ $$aValero O.
000118140 700__ $$0(orcid)0000-0002-1581-3085$$aPalacio J.$$uUniversidad de Zaragoza
000118140 700__ $$0(orcid)0000-0001-7610-6344$$aLuño I.$$uUniversidad de Zaragoza
000118140 700__ $$0(orcid)0000-0003-1728-900X$$aRosado B.$$uUniversidad de Zaragoza
000118140 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000118140 7102_ $$11009$$2617$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Medicina y Cirugía Animal
000118140 773__ $$g11, 11 (2021), 3121 [16 pp]$$pAnimals (Basel)$$tAnimals$$x2076-2615
000118140 8564_ $$s914756$$uhttps://zaguan.unizar.es/record/118140/files/texto_completo.pdf$$yVersión publicada
000118140 8564_ $$s2583945$$uhttps://zaguan.unizar.es/record/118140/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000118140 909CO $$ooai:zaguan.unizar.es:118140$$particulos$$pdriver
000118140 951__ $$a2023-12-19-14:45:44
000118140 980__ $$aARTICLE